We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers have shown that Nilvadipine can slow the rate of cognitive decline in very early- and early-stage Alzheimer’s patients and have received funding to develop improved versions.